Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial

Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide early readouts of biological activity and prognosis, offering the possibility for timely response‐guided treatment adjustment. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimbung, Siker, Markholm, Ida, Bjöhle, Judith, Lekberg, Tobias, von Wachenfeldt, Anna, Azavedo, Edward, Saracco, Ariel, Hellström, Mats, Veerla, Srinivas, Paquet, Eric, Bendahl, Pär‐Ola, Fernö, Mårten, Bergh, Jonas, Loman, Niklas, Hatschek, Thomas, Hedenfalk, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765477/
https://www.ncbi.nlm.nih.gov/pubmed/28940389
http://dx.doi.org/10.1002/ijc.31070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765477/
https://www.ncbi.nlm.nih.gov/pubmed/28940389
http://dx.doi.org/10.1002/ijc.31070

Ejemplares similares